Full-Time

Lead DevOps Engineer

Posted on 7/8/2026

Deadline 7/17/26
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

Compensation Overview

$93.5k - $187k/yr

Remote in USA + 2 more

More locations: California, USA | Washington, DC, USA

Remote

Remote role; US locations include California and Washington, DC.

Category
DevOps & Infrastructure (1)
Required Skills
Kubernetes
Docker
AWS
DevOps

Get referred to Cencora

Find people who can refer or advise you

Requirements
  • Bachelor's degree in computer science, software engineering, information technology, information systems, or a related field, or equivalent experience required.
  • 6+ years of experience in platform engineering, software engineering, infrastructure engineering, site reliability engineering, or a related field required.
Responsibilities
  • Lead the standardization of application deployments, containerization, and release processes across the organization.
  • Design and implement consistent, repeatable deployment pipelines that eliminate the friction and inconsistency that comes from teams each rolling their own solutions.
  • Containerize applications using Docker and orchestration platforms like ECS or Kubernetes.
  • Establish shared CI/CD frameworks.
  • Create the tooling and documentation that empowers engineering teams to ship reliably and confidently.
  • Work closely with development, infrastructure, and platform teams, you'll define best practices and golden paths that make the right way the easy way.
  • Influence how other engineers work and build consensus around shared standards.
  • Turn deployment chaos into a smooth, self-service experience for the entire organization.
Desired Qualifications
  • Master's degree in computer science, software engineering, information technology, information systems, or a related field, or equivalent experience preferred.
  • Certification in cloud platform engineering, infrastructure engineering, site reliability engineering, or equivalent preferred.
  • Deep hands-on experience with modern DevOps tooling including CI/CD systems such as GitHub Actions, GitLab CI, or Jenkins; infrastructure-as-code such as Terraform, Helm; and cloud platforms such as Amazon Web Services and Microsoft Azure.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology acquisition strengthens high-value specialty pharmaceutical positioning
  • New CFO Eva Boratto targets $300M savings using past Bath & Body Works expertise
  • International segment expects 8%-10% revenue growth in 2026 despite FX volatility

What critics are saying

  • Fraud investigation by Frank R. Cruz over May 6 Q2 $2.68B revenue miss risks lawsuits
  • Biosimilar conversions and IRA price cuts slashed revenue growth to 4%-6% from 7%-9%
  • Debt inadequately covered by operating cash flow limits flexibility amid US healthcare slowdown

What makes Cencora unique

  • Leads global pharma distribution with $300B+ revenue and Fortune 500 rank #10
  • Integrates specialty pharmacy, data analytics, and supply chain solutions uniquely
  • Pioneers Nucleus inventory tech for 20+ specialty practices with real-time tracking

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE